Compugen Ltd. (CGEN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe.
Analysis Summary
Compugen Ltd. reported revenue of $72.8M in the most recent fiscal year, growing at a 5-year CAGR of 105.2%.
Trailing-twelve-month margins: gross margin 86.9%, operating margin 40.9%, net margin 47.6%.
At the current price of $2.46, CGEN trades at a P/E of 6.55 and an ROE of 42.57%. Market capitalisation stands at $233M.
Balance sheet quality for CGEN: current ratio of 6.6, net cash position of $142.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is decent: free cash flow of $31.3M represents 89% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $2.46 |
| Market Cap | $233M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 6.55 |
| Price / Book | 2.62 |
| EV / EBITDA | 6.74 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 42.57% |
| Return on Invested Capital | 26.00% |
| Return on Assets | 25.43% |
| Gross Margin | 86.89% |
| Operating Margin | 40.94% |
| Net Margin | 47.55% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 5.72 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -0.38 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CGEN | Compugen Ltd. | $233M | 6.55 | 2.62 | 42.6% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Price Performance
| 1 month | +0.82% |
| 3 months | +22.39% |
| Year-to-date | +60.78% |
| 1 year | +83.58% |
| 3 years | +141.18% |
52-Week Range
| 52-week High | $3.24 |
| 52-week Low | $1.30 |
| Avg Volume (90d) | 353K |
Related companies: CRBP · CRDF · CYBN · IPHA · MIST · MOLN · NVCT
Explore sector: Healthcare · Biotechnology
More sections of CGEN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks